Replies to post #198967 on Biotech Values

[DewDiligence]

ILMN/GRAIL—…such a test [for general screening] will greatly increase worry, scans, surgery and chemo without having a dramatic impact on outcomes.

Third-party payers won’t reimburse users for such a test, even if it’s priced at only a few hundred dollars.